首页|Anemoside B4 inhibits SARS-CoV-2 replication in vitro and in vivo

Anemoside B4 inhibits SARS-CoV-2 replication in vitro and in vivo

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
Objective:Anemoside B4(AB4),the most abundant triterpenoidal saponin isolated from Pulsatilla chinen-sis,inhibited influenza virus FM1 or Klebsiella pneumoniae-induced pneumonia.However,the anti-SARS-CoV-2 effect of AB4 has not been unraveled.Therefore,this study aimed to determine the antiviral activ-ity and potential mechanism of AB4 in inhibiting human coronavirus SARS-CoV-2 in vivo and in vitro.Methods:The cytotoxicity of AB4 was evaluated using the Cell Counting Kit-8(CCK8)assay.SARS-CoV-2 infected HEK293T,HPAEpiC,and Vero E6 cells were used for in vitro assays.The antiviral effect of AB4 in vivo was evaluated by SARS-CoV-2-infected hACE2-IRES-luc transgenic mouse model.Furthermore,label-free quantitative proteomics and bioinformatic analysis were performed to explore the potential antiviral mechanism of action of AB4.Type Ⅰ IFN signaling-associated proteins were assessed using Western blotting or immumohistochemical staining.Results:The data showed that AB4 reduced the propagation of SARS-CoV-2 along with the decreased Nucleocapsid protein(N),Spike protein(S),and 3C-like protease(3CLpro)in HEK293T cells.In vivo antivi-ral activity data revealed that AB4 inhibited viral replication and relieved pneumonia in a SARS-CoV-2 infected mouse model.We further disclosed that the antiviral activity of AB4 was associated with the enhanced interferon(IFN)-β response via the activation of retinoic acid-inducible gene I(RIG-1)like receptor(RLP)pathways.Additionally,label-free quantitative proteomic analyses discovered that 17 pro-teins were significantly altered by AB4 in the SARS-CoV-2 coronavirus infections cells.These proteins mainly clustered in RNA metabolism.Conclusion:Our results indicated that AB4 inhibited SARS-CoV-2 replication through the RLR pathways and moderated the RNA metabolism,suggesting that it would be a potential lead compound for the development of anti-SARS-CoV-2 drugs.

anemoside B4interferonRNA metabolismquantitative proteomicsSARS-CoV-2

Mingyue Xiao、Ronghua Luo、Qinghua Liang、Honglv Jiang、Yanli Liu、Guoqiang Xu、Hongwei Gao、Yongtang Zheng、Qiongming Xu、Shilin Yang

展开 >

College of Pharmaceutical Sciences,Soochow University,Suzhou 215123,China

Key Laboratory of Animal Models and Human Disease Mechanisms of Chinese Academy of Sciences,KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases,Kunming Institute of Zoology,Chinese Academy of Sciences,Kunming 650223,China

Jiangsu Key Laboratory of Neuropsychiatric Diseases and Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases,Soochow University,Suzhou 215123,China

College of Pharmacy,Guangxi University of Chinese Medicine,Nanning 530000,China

展开 >

National Natural Science Foundation of ChinaNational Natural Science Foundation of ChinaPriority Academic Program Development(PAPD)of Jiangsu Higher Education Institutions

8234108782073912

2024

10.1016/j.chmed.2023.09.005

中草药(英文版)
天津药物研究院 中国医学科学院药用植物研究所

中草药(英文版)

CSTPCD
影响因子：0.6
ISSN：1674-6384
年,卷(期)：2024.16(1)
  • 15